Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 109 Show results per page	View Search Criteria \| Help With Results

Last Modified: 1/28/2009 First Published: 10/25/2004


1.		Phase III Randomized Study of Whole Brain Radiotherapy and Stereotactic Radiosurgery With Versus Without Temozolomide or Erlotinib in Patients With Non-Small Cell Lung Cancer and Brain Metastases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				RTOG-0320 NCT00096265

Last Modified: 1/22/2009 First Published: 3/24/2005


2.		Phase III Randomized Study of Sublobar Resection With Versus Without Intraoperative Brachytherapy in High-Risk Patients With Stage I Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				ACOSOG-Z4032 SRCI, NCT00107172

Last Modified: 1/29/2009 First Published: 5/5/2006


3.		Phase III Randomized Study of Adjuvant Chemotherapy With or Without Bevacizumab in Patients With Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				ECOG-E1505 E1505, SWOG-E1505, CALGB-E1505, CAN-NCIC-E1505, NCCTG-E1505, NCT00324805

Last Modified: 1/24/2009 First Published: 9/10/2006


4.		Phase III Randomized Study of Stereotactic Radiosurgery With Versus Without Whole-Brain Radiotherapy in Patients With Cerebral Metastases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				NCCTG-N0574 N0574, ACOSOG-N0574, NCT00377156

Last Modified: 1/28/2009 First Published: 7/6/2007


5.		Phase III Randomized Study of Lobectomy Versus Sublobar Resection in Patients With Small Peripheral Stage IA Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				CALGB-140503 CALGB-140503, ECOG-40503, NCT00499330

Last Modified: 1/27/2009 First Published: 9/18/2007


6.		Phase III Randomized Study of High- Versus Standard-Dose Conformal Radiotherapy With Concurrent and Consolidation Chemotherapy Comprising Carboplatin and Paclitaxel in Patients With Newly Diagnosed, Unresectable Stage IIIA or IIIB Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				RTOG-0617 RTOG 0617, NCCTG-N0628, CALGB-30609, NCT00533949

Last Modified: 1/29/2009 First Published: 6/5/2008


7.		Phase III Randomized Study of Sunitinib Malate as Maintenance Therapy in Patients With Stage IIIB or IV Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Combination Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				CALGB-30607 CALGB 30607, NCT00693992

Last Modified: 1/29/2009 First Published: 8/19/2008


8.		Phase III Randomized Study of Pemetrexed Disodium Versus Erlotinib Hydrochloride As Second-Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				NCCTG-N0723 MARVEL, N0723, CALGB-30802, CAN-NCIC-BRC4, NCT00738881

First Published: 11/12/2008


9.		Phase III Randomized Study of Talactoferrin in Patients With Stage IIIB or IV Non-Small Cell Lung Cancer Who Have Failed Two of More Prior Treatment Regimens

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI, Pharmaceutical / Industry				NCI-09-C-0018 09-C-0018, AGENNIX-LF-0207, NCT00707304

Last Modified: 12/9/2008 First Published: 12/23/2003


10.		Phase I/II Study of Vaccination Comprising a-1,3-Galactosyltransferase-Expressing Allogeneic Tumor Cells (HyperAcute™ Lung Cancer Vaccine) in Patients With Advanced Refractory or Recurrent Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI, Pharmaceutical / Industry				NCI-04-C-0049 NLGC-0101, NCT00075790

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute